Conference call Report on Operations 2017

Invitation to attend Vitrolife’s conference call regarding presentation of the Report on Operations 2017. The presentation will be held in English.

Time: Thursday February 8, 2018 at 10.00 a.m. CET.

Registration can preferably be done 10-15 minutes before the conference start time on:

Sweden dial in number: +46 (0)8 5661 9445 

International dial in number: +44 (0)1452 541003 

Conference name: Vitrolife, conference ID: 3686368

Vitrolife participants:
Thomas Axelsson, CEO

Mikael Engblom, CFO

The press release for Vitrolife’s Report on Operations will be released at 8.30 CET on the same day.

Before the conference call, slides will be available at the company web page
, http://www.vitrolife.com. 

A recorded version of the presentation will be available for seven days on number 

+44 (0)1452 550000 (International), access code 3686368.

Gothenburg, January 30, 2018

VITROLIFE AB (publ)

For further information, please contact:
Mikael Engblom, CFO, +46 (0) 31 721 80 14

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife has approximately 370 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

Tags:

About Us

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets products for assisted reproduction. Vitrolife has about 370 employees and the company’s products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Subscribe

Documents & Links